Ozempic Rival Delivers 25% Weight Loss at Highest Dose in Phase 3 Trial - ScienceAlert

Fecha de publicación: 3 de octubre de 2026, 1:02

Ozempic Rival Delivers 25% Weight Loss at Highest Dose in Phase 3 Trial ScienceAlert Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s cnbc.com Blockbuster retatrutide trial signals a ‘new high-water mark’ for weight-loss drugs Scientific American ‘Godzilla’…